New drug combo for advanced thyroid cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of advanced thyroid cancer that cannot be removed by surgery or has spread (anaplastic, poorly differentiated, or radioactive iodine-refractory).
- If you have anaplastic or poorly differentiated thyroid cancer, you either have no certain genetic changes (BRAF, RET, NTRK, ALK) or have had those changes and standard targeted therapy did not work.
- If you have radioactive iodine-refractory thyroid cancer, your cancer did not respond to radioactive iodine treatment or you have tried at least one targeted therapy (TKI).
- You are able to take care of yourself (ECOG score 0-2) and have adequate organ function (kidney, liver, blood counts).
- You have not had treatment targeting the TROP2 protein or a topoisomerase I inhibitor antibody-drug conjugate before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pucotenlimab, for people with advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread. The goal is to see if this treatment is safe and works well, especially for those with a protein called TROP2 on their cancer cells.
This study tests a new combination of two drugs—sacituzumab tirumotecan (a targeted therapy) plus an immunotherapy—for people whose head and neck cancer has returned or spread after standard treatment. The goal is to see if this combination can shrink tumors and delay cancer growth.
This study tests a new combination of two drugs (sacituzumab tirumotecan and another drug) for people with advanced esophageal cancer. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Hear when a new Poorly Differentiated Thyroid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.